$AWH
Aspira Women's Health Inc.

2022 Q1 Form 10-K Financial Statement

#000092661722000014 Filed on March 31, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $1.893M $1.851M $6.812M
YoY Change 26.54% 27.66% 46.46%
Cost Of Revenue $932.0K $837.0K $3.750M
YoY Change 4.37% -31.39% 9.81%
Gross Profit $961.0K $1.014M $3.062M
YoY Change 59.37% 340.87% 147.73%
Gross Profit Margin 50.77% 54.78% 44.95%
Selling, General & Admin $8.860M $8.507M $30.34M
YoY Change 57.74% 52.73% 77.31%
% of Gross Profit 921.96% 838.95% 990.95%
Research & Development $1.348M $1.453M $5.314M
YoY Change 54.59% 99.04% 152.57%
% of Gross Profit 140.27% 143.29% 173.55%
Depreciation & Amortization $64.00K $64.00K $302.0K
YoY Change -28.89% -28.89% 13.96%
% of Gross Profit 6.66% 6.31% 9.86%
Operating Expenses $10.21M $9.960M $35.66M
YoY Change 57.31% 58.1% 85.55%
Operating Profit -$9.247M -$8.946M -$32.60M
YoY Change 57.1% 47.38% 81.27%
Interest Expense -$18.00K -$13.00K -$48.00K
YoY Change -10.0% -580.0%
% of Operating Profit
Other Income/Expense, Net -$3.000K -$2.000K $981.0K
YoY Change -70.0% 1386.36%
Pretax Income -$9.268M -$8.961M $31.66M
YoY Change 56.55% 47.38% 76.83%
Income Tax
% Of Pretax Income
Net Earnings -$9.268M -$8.961M -$31.66M
YoY Change 56.55% 47.38% 76.83%
Net Earnings / Revenue -489.59% -484.12% -464.8%
Basic Earnings Per Share -$1.24 -$0.28
Diluted Earnings Per Share -$82.65K -$79.92K -$0.28
COMMON SHARES
Basic Shares Outstanding 112.1M 112.1M 111.2M
Diluted Shares Outstanding 7.476M 111.2M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.86M $37.18M $37.18M
YoY Change -54.79% 123.98% 123.98%
Cash & Equivalents $26.86M $37.18M $37.18M
Short-Term Investments
Other Short-Term Assets $1.620M $1.624M $1.624M
YoY Change 62.0% 47.64% 47.64%
Inventory $189.0K $174.0K $174.0K
Prepaid Expenses
Receivables $1.136M $1.027M $1.027M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $29.80M $40.01M $40.01M
YoY Change -51.44% 115.05% 115.08%
LONG-TERM ASSETS
Property, Plant & Equipment $480.0K $464.0K $810.0K
YoY Change -9.94% -20.41% -19.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $14.00K $264.0K
YoY Change 7.69%
Total Long-Term Assets $1.061M $1.074M $1.074M
YoY Change 14.83% 7.19% 7.4%
TOTAL ASSETS
Total Short-Term Assets $29.80M $40.01M $40.01M
Total Long-Term Assets $1.061M $1.074M $1.074M
Total Assets $30.86M $41.08M $41.08M
YoY Change -50.46% 109.53% 109.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.298M $1.501M $1.501M
YoY Change -18.21% 36.08% 36.45%
Accrued Expenses $4.035M $5.299M $5.359M
YoY Change 16.25% 46.46% 48.86%
Deferred Revenue
YoY Change
Short-Term Debt $519.0K $779.0K $779.0K
YoY Change 29.75% 27.5% 29.83%
Long-Term Debt Due $223.0K $201.0K $201.0K
YoY Change 10.95% -68.84% -79.9%
Total Short-Term Liabilities $6.139M $7.840M $7.840M
YoY Change 0.64% 30.67% 22.5%
LONG-TERM LIABILITIES
Long-Term Debt $2.646M $2.718M $2.718M
YoY Change -2.65% -21.83% -12.32%
Other Long-Term Liabilities $332.0K $349.0K $349.0K
YoY Change -17.0% -12.75% -12.75%
Total Long-Term Liabilities $2.646M $2.718M $3.067M
YoY Change -2.65% -21.83% -12.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.139M $7.840M $7.840M
Total Long-Term Liabilities $2.646M $2.718M $3.067M
Total Liabilities $9.117M $10.91M $10.91M
YoY Change -8.83% 10.33% 10.17%
SHAREHOLDERS EQUITY
Retained Earnings -$481.0M -$471.7M
YoY Change 7.85% 7.19%
Common Stock $112.0K $112.0K
YoY Change 0.0% 6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.74M $30.17M $30.17M
YoY Change
Total Liabilities & Shareholders Equity $30.86M $41.08M $41.08M
YoY Change -50.46% 109.53% 109.59%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$9.268M -$8.961M -$31.66M
YoY Change 56.55% 47.38% 76.83%
Depreciation, Depletion And Amortization $64.00K $64.00K $302.0K
YoY Change -28.89% -28.89% 13.96%
Cash From Operating Activities -$10.17M -$7.649M -$27.40M
YoY Change 93.59% 61.03% 85.93%
INVESTING ACTIVITIES
Capital Expenditures $82.00K -$30.00K $184.0K
YoY Change 100.0% -86.36% -62.45%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$82.00K -$30.00K -$184.0K
YoY Change 100.0% -86.36% -62.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $48.24M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -70.00K -11.00K 48.38M
YoY Change -100.15% -100.4% 140.07%
NET CHANGE
Cash From Operating Activities -10.17M -7.649M -27.40M
Cash From Investing Activities -82.00K -30.00K -184.0K
Cash From Financing Activities -70.00K -11.00K 48.38M
Net Change In Cash -10.33M -7.690M 20.80M
YoY Change -124.16% 249.55% 322.06%
FREE CASH FLOW
Cash From Operating Activities -$10.17M -$7.649M -$27.40M
Capital Expenditures $82.00K -$30.00K $184.0K
Free Cash Flow -$10.26M -$7.619M -$27.58M
YoY Change 93.64% 68.19% 81.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 awh Effective Income Tax Rate Reconciliation Net Operating Loss Carry Forwards
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwards
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000926617
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
CY2020 us-gaap Dilutive Securities
DilutiveSecurities
CY2021 dei City Area Code
CityAreaCode
 
CY2021 dei Local Phone Number
LocalPhoneNumber
 
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-34810
CY2021 dei Entity Registrant Name
EntityRegistrantName
Aspira Women’s Health Inc.
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
AWH
CY2021 us-gaap Dilutive Securities
DilutiveSecurities
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
CY2021 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
477546462
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
112138741
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
Austin, Texas
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37180000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16631000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1027000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
865000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1624000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1077000
CY2021Q4 us-gaap Inventory Net
InventoryNet
174000
CY2020Q4 us-gaap Inventory Net
InventoryNet
30000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
40005000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18603000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
464000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
583000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
346000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
406000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000
CY2021Q4 us-gaap Assets
Assets
41079000
CY2020Q4 us-gaap Assets
Assets
19605000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1501000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1103000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5299000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3618000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
201000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
645000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
779000
CY2020Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
611000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
60000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7840000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6000000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2718000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3477000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
349000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
409000
CY2021Q4 us-gaap Liabilities
Liabilities
10907000
CY2020Q4 us-gaap Liabilities
Liabilities
9886000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112138741
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112138741
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104619876
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104619876
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
112000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
105000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
501788000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
449680000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-471728000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440066000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9719000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41079000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19605000
CY2021 us-gaap Revenues
Revenues
6812000
CY2020 us-gaap Revenues
Revenues
4651000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3750000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3415000
CY2021 us-gaap Gross Profit
GrossProfit
3062000
CY2020 us-gaap Gross Profit
GrossProfit
1236000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5314000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2104000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17086000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8843000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13257000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8270000
CY2021 us-gaap Operating Expenses
OperatingExpenses
35657000
CY2020 us-gaap Operating Expenses
OperatingExpenses
19217000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-32595000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-17981000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-48000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
981000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
66000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-31662000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17905000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
111210614
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100723303
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8738000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17905000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1637000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
182000
CY2020 awh Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5060000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
384000
CY2020 awh Common Stock And Warrants Issued In Conjunction With Private Placement Sale Net Of Issuance Costs
CommonStockAndWarrantsIssuedInConjunctionWithPrivatePlacementSaleNetOfIssuanceCosts
10641000
CY2020 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1366000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9719000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-31662000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
718000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47858000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
455000
CY2021 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
3084000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-31662000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17905000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
37000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
26000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
302000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
265000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3539000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1548000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2021 awh Forgiveness Of Paycheck Protection Program Loan
ForgivenessOfPaycheckProtectionProgramLoan
1006000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
162000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-59000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
548000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
319000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
144000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2248000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1594000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27395000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14734000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
490000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-184000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-490000
CY2021 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
198000
CY2020 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
192000
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2000000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
718000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1637000
CY2020 awh Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
1006000
CY2021 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation with no material effect on the consolidated financial statements. On the consolidated balance sheet, short-term debt of $400,000 was reclassified to long-term debt.
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5060000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11025000
CY2020 awh Payment Of Stock Issuance Costs For Private Placement
PaymentOfStockIssuanceCostsForPrivatePlacement
384000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48235000
CY2021 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
377000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48378000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20152000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20799000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4928000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16631000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11703000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16631000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37180000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16631000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16631000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
77000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
37000
CY2020 awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
354000
CY2020 awh Net Changes In Accounts Payable Related To Capital Expenditures
NetChangesInAccountsPayableRelatedToCapitalExpenditures
8000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-471728000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
‎ Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1220500
CY2021 us-gaap Finite Lived Intangible Assets Cost Incurred To Renew Or Extend
FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend
202000
CY2020 us-gaap Finite Lived Intangible Assets Cost Incurred To Renew Or Extend
FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend
322000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
409000
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3249000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3160000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2785000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2577000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
464000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
583000
CY2021 us-gaap Depreciation
Depreciation
302000
CY2020 us-gaap Depreciation
Depreciation
265000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2652000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1874000
CY2021Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
382000
CY2020Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
616000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1992000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
803000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
273000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
325000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5299000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3618000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
2919000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
4122000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
201000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
645000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2718000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3477000
CY2021Q4 us-gaap Contractual Obligation
ContractualObligation
2933000
CY2021Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
204000
CY2021Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
406000
CY2021Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
452000
CY2021Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
461000
CY2021Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
341000
CY2021Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
1069000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
95000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
106000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
116000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
124000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
64000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
505000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
96000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0933
CY2021 us-gaap Royalty Expense
RoyaltyExpense
263000
CY2020 us-gaap Royalty Expense
RoyaltyExpense
181000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3925409
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
356940
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1388900
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6504934
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1417272
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4020634
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
76742
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31662000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111210614
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31662000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111210614
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17905000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100723303
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17905000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100723303
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10257908
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8212112
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
10955683
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
95626
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3729204
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6612878
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.67
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
303995
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M28D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3925409
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.46
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1105675
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.48
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1220500
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.75
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8212112
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.49
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42833712
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M3D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4020634
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.22
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
557566
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.29
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1417272
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.34
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10257908
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.96
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3797181
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M8D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4773394
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.61
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2182917
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M28D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5484514
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.14
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1614267
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y9M7D
CY2021 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.47
CY2021 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
7.79
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
10257908
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38268000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32740000
CY2021Q4 awh Deferred Tax Assets Intangible Assets Amortization
DeferredTaxAssetsIntangibleAssetsAmortization
2404000
CY2020Q4 awh Deferred Tax Assets Intangible Assets Amortization
DeferredTaxAssetsIntangibleAssetsAmortization
1873000
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.96
CY2021 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y5M8D
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
4773394
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
1.61
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2903000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4325000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3439000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3254000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.89
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0063
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0071
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y9M18D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y10M24D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.94
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.87
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
31662000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
17905000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
633000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
622000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
587000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
41892000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35235000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41892000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35195000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
40000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
40000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
40000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.19
CY2020 awh Effective Income Tax Rate Reconciliation Net Operating Loss Carry Forwards
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwards
-0.02
CY2021 awh Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.01
CY2020 awh Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41892000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35195000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10644000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
65000
CY2020 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
192000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10517000
CY2021 awh Unrecognized Tax Benefits Return To Provision True Up
UnrecognizedTaxBenefitsReturnToProvisionTrueUp
-9000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
508000
CY2021 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
435000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10581000
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0000926617-22-000014-index-headers.html Edgar Link pending
0000926617-22-000014-index.html Edgar Link pending
0000926617-22-000014.txt Edgar Link pending
0000926617-22-000014-xbrl.zip Edgar Link pending
awh-20211231.xsd Edgar Link pending
awh-20211231x10k.htm Edgar Link pending
awh-20211231x10k_htm.xml Edgar Link completed
awh-20211231xex21_0.htm Edgar Link pending
awh-20211231xex23_1.htm Edgar Link pending
awh-20211231xex31_1.htm Edgar Link pending
awh-20211231xex31_2.htm Edgar Link pending
awh-20211231xex32_1.htm Edgar Link pending
awh-20211231xex4_7.htm Edgar Link pending
awh-20211231_cal.xml Edgar Link unprocessable
awh-20211231_def.xml Edgar Link unprocessable
awh-20211231_lab.xml Edgar Link unprocessable
awh-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending